Kathleen Ford - Nov 13, 2025 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Operating Officer
Signature
Teresa Bair, Attorney-in-fact for Kathleen Ford
Stock symbol
KURA
Transactions as of
Nov 13, 2025
Transactions value $
-$77,143
Form type
4
Date filed
11/14/2025, 08:00 PM
Previous filing
Sep 29, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
FORD KATHLEEN Chief Operating Officer C/O KURA ONCOLOGY, INC., 4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO Teresa Bair, Attorney-in-fact for Kathleen Ford 2025-11-14 0001785406

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +48.9K +77.16% $0.00 112K Nov 13, 2025 Direct
transaction KURA Common Stock Sale -$77.1K -6.9K -6.15% $11.18 105K Nov 14, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units ("PSUs") granted to the Reporting Person on May 31, 2023. Each PSU represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date. The performance criteria for one specified development milestone was determined to be met on November 13, 2025, resulting in the vesting of 1/6th of the underlying shares.